{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T10:36:45Z","timestamp":1770547005326,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13139-025-00963-9","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:12:38Z","timestamp":1761721958000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Status and Advancements in Radiotheranostics and Targeted Radionuclide Therapy in Malaysia"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4675-3078","authenticated-orcid":false,"given":"Muhammad Fakhrurazi Ahmad","family":"Fadzil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-4705","authenticated-orcid":false,"given":"Zarif","family":"Ashhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-7822","authenticated-orcid":false,"given":"Azahari","family":"Kasbollah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaitulhusna Md","family":"Safee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti Fazira Edzua","family":"Jamaludin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0978-4716","authenticated-orcid":false,"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"963_CR1","first-page":"94","volume":"9","author":"D Tapas","year":"2016","unstructured":"Tapas D, Sharmila B. Theranostic applications of Lutetium-177 in radionuclide therapy. Curr Radiopharm. 2016;9:94\u2013101.","journal-title":"Curr Radiopharm"},{"key":"963_CR2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/17434440.2020.1741348","volume":"17","author":"L Filippi","year":"2020","unstructured":"Filippi L, Chiaravalloti A, Schillaci O, Cianni R, Bagni O. Theranostic approaches in nuclear medicine: current status and future prospects. Expert Rev Med Devices. 2020;17:331\u201343.","journal-title":"Expert Rev Med Devices"},{"key":"963_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s13139-018-0562-5","volume":"53","author":"A Al-Ibraheem","year":"2019","unstructured":"Al-Ibraheem A, Mohamedkhair A. Current status of theranostics in Jordan. Nucl Med Mol Imaging. 2019;53:7\u201310.","journal-title":"Nucl Med Mol Imaging"},{"key":"963_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.124.269215","volume":"66","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, et al. Consensus nomenclature for radionuclide therapy: initial recommendations from nuclear medicine global initiative. J Nucl Med. 2025;66:757.","journal-title":"J Nucl Med"},{"issue":"1","key":"963_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.dsx.2008.04.005","volume":"4","author":"SH Habib","year":"2010","unstructured":"Habib SH, Saha S. Burden of non-communicable disease: global overview. Diabetes Metab Syndr. 2010;4(1):41\u20137.","journal-title":"Diabetes Metab Syndr"},{"key":"963_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.semnuclmed.2024.02.003","volume":"54","author":"A Al-Ibraheem","year":"2024","unstructured":"Al-Ibraheem A, Zimmermann R, Abdlkadir AS, Herrmann K. Radiotheranostics global market and future developments. Semin Nucl Med. 2024;54:622\u201333.","journal-title":"Semin Nucl Med"},{"key":"963_CR7","first-page":"2563","volume":"11","author":"RR Marzo","year":"2022","unstructured":"Marzo RR, Bhattacharya S, Aye SS, Tripathi S, Naing TW, Soe MM, et al. Study on the quality of life among cancer survivors attending a tertiary care cancer center in Malaysia. J Public Health Res. 2022;11:2563.","journal-title":"J Public Health Res"},{"key":"963_CR8","unstructured":"Ministry of Health Malaysia. National Strategic Plan for Cancer Control Programme 2021\u20132025. 2021.https:\/\/www.moh.gov.my\/moh\/resources\/Penerbitan\/Rujukan\/NCD\/National_Strategic_Plan_for_Cancer_Control_Programme_2021-2025.pdf. Accessed 13 December 2024."},{"key":"963_CR9","first-page":"622","volume":"69","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Abdlkadir AS, Albalooshi B, Alkuwari M, Al Mahariq D, Al-Nabhani K, et al. Current status of theranostics in West asia: a country-based surveillance study. Nucl Med Mol Imaging. 2025;69:622\u201333.","journal-title":"Nucl Med Mol Imaging"},{"key":"963_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13139-019-00576-z","volume":"53","author":"KH Lin","year":"2019","unstructured":"Lin KH, Chen YW, Lee RC, Wang LW, Chou FI, Chang CW, et al. Nuclear theranostics in Taiwan. Nucl Med Mol Imaging. 2019;53:86\u201391.","journal-title":"Nucl Med Mol Imaging"},{"key":"963_CR11","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.acra.2024.11.064","volume":"32","author":"H Dadgar","year":"2025","unstructured":"Dadgar H, Norouzbeigi N, Assadi M, Jafari E, Al-Balooshi B, Al-Ibraheem A, et al. A prospective evaluation of chemokine receptor-4 (CXCR4) overexpression in high-grade glioma using \u2076\u2078Ga-Pentixafor (Pars-Cixafor\u2122) PET\/CT imaging. Acad Radiol. 2025;32:2247\u201356.","journal-title":"Acad Radiol"},{"key":"963_CR12","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.2967\/jnumed.123.266968","volume":"65","author":"W Yang","year":"2024","unstructured":"Yang W, Kang F, Chen Y, Zhu Z, Wang F, Qin C, et al. Landscape of nuclear medicine in China and its progress on theranostics. J Nucl Med. 2024;65:S29\u201337.","journal-title":"J Nucl Med"},{"key":"963_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.7150\/ntno.64141","volume":"6","author":"H Duan","year":"2022","unstructured":"Duan H, Iagaru A, Aparici CM. Radiotheranostics \u2013 precision medicine in nuclear medicine and molecular imaging. Nanotheranostics. 2022;6:103\u201317.","journal-title":"Nanotheranostics"},{"key":"963_CR14","unstructured":"International Atomic Energy Agency. Technical meeting on commercial products and services of research reactors- applications and services at PUSPATI TRIGA reactor in malaysia: current status and outlook. Vienna: IAEA; 2011."},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"220157","DOI":"10.1148\/rycan.220157","volume":"5","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoglu K, et al. A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer. 2023;5:220157.","journal-title":"Radiol Imaging Cancer"},{"key":"963_CR16","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s42452-020-03524-1","volume":"2","author":"S Hasan","year":"2020","unstructured":"Hasan S, Prelas MA. Molybdenum-99 production pathways and the sorbents for \u2079\u2079Mo\/\u2079\u2079Tc generator systems using (n, \u03b3) \u2079\u2079Mo: a review. SN Appl Sci. 2020;2:1782.","journal-title":"SN Appl Sci"},{"key":"963_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","volume":"49","author":"A Dash","year":"2015","unstructured":"Dash A, Pillai MR, Knapp FF Jr. Production of \u00b9\u2077\u2077Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49:85\u2013107.","journal-title":"Nucl Med Mol Imaging"},{"key":"963_CR18","first-page":"40","volume":"12","author":"MFA Fadzil","year":"2015","unstructured":"Fadzil MFA, Hasan S, Janib SNM, Kasbollah A, Wafa SAF. A survey on the usage and demand of medical radioisotope & radiopharmaceuticals in Malaysia. J Nucl Relat Technol. 2015;12:40\u201355.","journal-title":"J Nucl Relat Technol"},{"key":"963_CR19","doi-asserted-by":"publisher","first-page":"e15734056270935","DOI":"10.2174\/0115734056270935231113035620","volume":"20","author":"Z Ashhar","year":"2024","unstructured":"Ashhar Z, Ahmad Fadzil MF, Hassan H, Othman MF, Md Hassan MB, Chun Vui VY, et al. The potential of radiolabeled bisphosphonates in SPECT and PET for bone imaging. Curr Med Imaging. 2024;20:e15734056270935.","journal-title":"Curr Med Imaging"},{"key":"963_CR20","doi-asserted-by":"publisher","first-page":"111161","DOI":"10.1016\/j.apradiso.2023.111161","volume":"205","author":"Z Ashhar","year":"2024","unstructured":"Ashhar Z, Ahmad Fadzil MF, Md Safee Z, Aziz F, Ibarhim UH, Nik Afinde NMF, et al. Performance evaluation of Gallium-68 radiopharmaceuticals production using liquid target PETtrace 800 cyclotron. Appl Radiat Isot. 2024;205:111161.","journal-title":"Appl Radiat Isot"},{"key":"963_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3390\/pharmaceutics15010070","volume":"15","author":"Z Ashhar","year":"2023","unstructured":"Ashhar Z, Ahmad Fadzil MF, Othman MF, Yusof NA, Abdul Onny MA, Mat Ail N, et al. Cyclotron production of Gallium-68 radiopharmaceuticals using the \u2076\u2078Zn(p,n)\u2076\u2078Ga reaction and their regulatory aspects. Pharmaceutics. 2023;15:70.","journal-title":"Pharmaceutics"},{"key":"963_CR22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s00259-022-05694-z","volume":"49","author":"H Hendrikse","year":"2022","unstructured":"Hendrikse H, Kiss O, Kunikowska J, Wadsak W, Decristoforo C, Patt M. EANM position on the in-house preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022;49:1095\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"963_CR23","doi-asserted-by":"publisher","first-page":"012017","DOI":"10.1088\/1742-6596\/851\/1\/012017","volume":"851","author":"MA Said","year":"2017","unstructured":"Said MA, Masud MA, Zaini MZ, Salleh RA, Lee BN, Zainon R. Lu-177 DOTATATE dosimetry for neuroendocrine tumor: single center experience. J Phys Conf Ser. 2017;851:012017.","journal-title":"J Phys Conf Ser"},{"key":"963_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/S0960-894X(98)00187-5","volume":"8","author":"R Albert","year":"1998","unstructured":"Albert R, Smith-Jones P, Stolz B, Simeon C, Knecht H, Bruns C, et al. Direct synthesis of [DOTA-DPhe\u00b9]-octreotide and [DOTA-DPhe\u00b9, Tyr\u00b3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. Bioorg Med Chem Lett. 1998;8:1207\u201310.","journal-title":"Bioorg Med Chem Lett"},{"key":"963_CR25","doi-asserted-by":"publisher","first-page":"10960","DOI":"10.1021\/ic101378s","volume":"49","author":"V Kub\u00ed\u010dek","year":"2010","unstructured":"Kub\u00ed\u010dek V, Havl\u00ed\u010dkov\u00e1 J, Kotek J, Tircs\u00f3 G, Hermann P, T\u00f3th \u00c9, et al. Gallium(III) complexes of DOTA and DOTA-monoamide: kinetic and thermodynamic studies. Inorg Chem. 2010;49:10960\u20139.","journal-title":"Inorg Chem"},{"key":"963_CR26","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s00259-004-1702-y","volume":"32","author":"WAP Breeman","year":"2005","unstructured":"Breeman WAP, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with \u2076\u2078Ga. Eur J Nucl Med Mol Imaging. 2005;32:478\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"963_CR27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.7150\/thno.3645","volume":"2","author":"RP Baum","year":"2012","unstructured":"Baum RP, Kulkarni HR. Theranostics: from molecular imaging using \u2076\u2078Ga-labeled tracers and PET\/CT to personalized radionuclide therapy \u2013 the bad Berka experience. Theranostics. 2012;2:437\u201347.","journal-title":"Theranostics"},{"key":"963_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12149-014-0898-6","volume":"29","author":"RA Werner","year":"2015","unstructured":"Werner RA, Bluemel C, Allen-Auerbach MS, Higuchi T, Herrmann K. \u2076\u2078Gallium- and \u2079\u2070Yttrium-\/\u00b9\u2077\u2077Lutetium: theranostic twins for diagnosis and treatment of NETs. Ann Nucl Med. 2015;29:1\u20137.","journal-title":"Ann Nucl Med"},{"key":"963_CR29","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1021\/ic00094a021","volume":"33","author":"K Kumar","year":"1994","unstructured":"Kumar K, Chang CA, Francesconi LC, Dischino DD, Malley MF, Gougoutas JZ, et al. Synthesis, stability, and structure of gadolinium(III) and yttrium(III) macrocyclic poly(amino carboxylates). Inorg Chem. 1994;33:3567\u201375.","journal-title":"Inorg Chem"},{"key":"963_CR30","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ccr.2009.03.013","volume":"253","author":"N Viola-Villegas","year":"2009","unstructured":"Viola-Villegas N, Doyle RP. The coordination chemistry of 1,4,7,10-tetraazacyclododecane-N,N\u2032,N\u2033,N\u2032\u2033-tetraacetic acid (H\u2084DOTA): structural overview and analyses on structure\u2013stability relationships. Coord Chem Rev. 2009;253:1906\u201325.","journal-title":"Coord Chem Rev"},{"key":"963_CR31","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1021\/ic00235a031","volume":"25","author":"MF Loncin","year":"1986","unstructured":"Loncin MF, Desreux JF, Merciny E. Coordination of lanthanides by two polyamino polycarboxylic macrocycles: formation of highly stable lanthanide complexes. Inorg Chem. 1986;25:2646\u20138.","journal-title":"Inorg Chem"},{"key":"963_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0020-1693(00)80229-7","volume":"190","author":"ET Clarke","year":"1991","unstructured":"Clarke ET, Martell AE. Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles. Inorg Chim Acta. 1991;190:37\u201346.","journal-title":"Inorg Chim Acta"},{"key":"963_CR33","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1007\/s00259-008-0816-z","volume":"35","author":"M Eder","year":"2008","unstructured":"Eder M, W\u00e4ngler B, Knackmuss S, LeGall F, Little M, Haberkorn U, et al. Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for \u2076\u2078Ga-labeled small Recombinant antibodies. Eur J Nucl Med Mol Imaging. 2008;35:1878\u201386.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"963_CR34","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull WE, W\u00e4ngler C, Mier W, et al. \u2076\u2078Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23:688\u201397.","journal-title":"Bioconjug Chem"},{"key":"963_CR35","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1021\/mp9000712","volume":"6","author":"SA Kularatne","year":"2009","unstructured":"Kularatne SA, Zhou Z, Yang J, Post CB, Low PS. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted \u2079\u2079Tc-radioimaging agents. Mol Pharm. 2009;6:790\u2013800.","journal-title":"Mol Pharm"},{"key":"963_CR36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/C3CS60304K","volume":"43","author":"EW Price","year":"2014","unstructured":"Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43:260\u201390.","journal-title":"Chem Soc Rev"},{"key":"963_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0020-1693(00)81019-1","volume":"85","author":"CH Taliaferro","year":"1984","unstructured":"Taliaferro CH, Martell A. New multidentate ligands. XXIV. Disodium-N,N\u2032-bis(2-hydroxy-5-sulfobenzyl)-ethylenediaminediacetic acid, a new chelating ligand for trivalent metal ions. Inorg Chim Acta. 1984;85:9\u201315.","journal-title":"Inorg Chim Acta"},{"key":"963_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-014-0063-1","volume":"4","author":"M Weineisen","year":"2014","unstructured":"Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4:63.","journal-title":"EJNMMI Res"},{"key":"963_CR39","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/acs.bioconjchem.5b00679","volume":"27","author":"S Ray Banerjee","year":"2016","unstructured":"Ray Banerjee S, Chen Z, Pullambhatla M, Lisok A, Chen J, Mease RC, et al. Preclinical comparative study of \u2076\u2078Ga-labeled DOTA, NOTA, and HBED-CC chelated radiotracers for targeting PSMA. Bioconjug Chem. 2016;27:1447\u201355.","journal-title":"Bioconjug Chem"},{"key":"963_CR40","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.2967\/jnumed.115.171249","volume":"57","author":"A Amor-Coarasa","year":"2016","unstructured":"Amor-Coarasa A, Schoendorf M, Meckel M, Vallabhajosula S, Babich JW. Comprehensive quality control of the ITG \u2076\u2078Ge\/\u2076\u2078Ga generator and synthesis of \u2076\u2078Ga-DOTATOC and \u2076\u2078Ga-PSMA-HBED-CC for clinical imaging. J Nucl Med. 2016;57:1402.","journal-title":"J Nucl Med"},{"key":"963_CR41","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1021\/jm800765e","volume":"51","author":"C Barinka","year":"2008","unstructured":"Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008;51:7737\u201343.","journal-title":"J Med Chem"},{"key":"963_CR42","doi-asserted-by":"publisher","first-page":"6932","DOI":"10.1158\/0008-5472.CAN-09-1682","volume":"69","author":"SM Hillier","year":"2009","unstructured":"Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69:6932\u201340.","journal-title":"Cancer Res"},{"issue":"15","key":"963_CR43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/cancers13153715","volume":"13","author":"KE Seifert","year":"2021","unstructured":"Seifert KE, Seifert R, Kessel K, Roll W, Schlack K, Boegemann M, et al. Lutetium-177 labelled PSMA targeted therapy in advanced prostate cancer: current status and future perspectives. Cancers (Basel). 2021;13(15):371.","journal-title":"Cancers (Basel)"},{"key":"963_CR44","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s00259-025-07168-4","volume":"52","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Moghrabi S, Sathekge MM, Abdlkadir AS. Evaluating xerostomia as a side effect of [\u00b2\u00b2\u2075Ac]Ac-PSMA therapy in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025;52:2906\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"963_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"963_CR46","first-page":"794","volume":"79","author":"Z Ashhar","year":"2024","unstructured":"Ashhar Z, Fadzil MF, Said MA, Mujahid M, Suppiah S. Quality control of actinium-225 radiopharmaceuticals: current challenges and solutions in Malaysia. Med J Malaysia. 2024;79:794\u20139.","journal-title":"Med J Malaysia"},{"key":"963_CR47","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.7150\/thno.106108","volume":"15","author":"S Ruzzeh","year":"2025","unstructured":"Ruzzeh S, Abdlkadir AS, Paez D, Kang KW, Watabe T, Moghrabi S, et al. Therapeutic potential of FAPI RLT in oncology: a systematic review. Theranostics. 2025;15:4084\u2013100.","journal-title":"Theranostics"},{"issue":"2","key":"963_CR48","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3390\/diagnostics15020218","volume":"15","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Abdlkadir AS, Al-Rasheed U, Al-Adhami D, Istatieh F, Anwar F, et al. First clinical experience of \u2076\u2078Ga-FAPI PET\/CT in tertiary cancer center: identifying pearls and pitfalls. Diagnostics (Basel). 2025;15(2):218.","journal-title":"Diagnostics (Basel)"},{"key":"963_CR49","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1007\/s00259-021-05392-2","volume":"48","author":"WV Vogel","year":"2021","unstructured":"Vogel WV, van der Marck SC, Versleijen MWJ. Challenges and future options for the production of lutetium-177. Eur J Nucl Med Mol Imaging. 2021;48:2329\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"963_CR50","first-page":"2430","volume":"65","author":"CK Ho","year":"2024","unstructured":"Ho CK, Kaur M. Terbium-161, a promising new theranostic radionuclide. J Nucl Med. 2024;65:2430.","journal-title":"J Nucl Med"},{"key":"963_CR51","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.2967\/jnumed.122.265291","volume":"64","author":"A Al-Ibraheem","year":"2023","unstructured":"Al-Ibraheem A, Doudeen RM, Juaidi D, Abufara A, Maus S. \u00b9\u2076\u00b9Tb-PSMA radioligand therapy: first-in-humans SPECT\/CT imaging. J Nucl Med. 2023;64:1322.","journal-title":"J Nucl Med"},{"key":"963_CR52","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41181-019-0063-6","volume":"4","author":"N Gracheva","year":"2019","unstructured":"Gracheva N, M\u00fcller C, Talip Z, Heinitz S, K\u00f6ster U, Zeevaart JR, et al. Production and characterization of no-carrier-added \u00b9\u2076\u00b9Tb as an alternative to the clinically-applied \u00b9\u2077\u2077Lu for radionuclide therapy. EJNMMI Radiopharm Chem. 2019;4:12.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"963_CR53","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.2967\/jnumed.123.265907","volume":"64","author":"R Zimmermann","year":"2023","unstructured":"Zimmermann R. Is actinium really happening? J Nucl Med. 2023;64:1516\u20138.","journal-title":"J Nucl Med"},{"key":"963_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13550-018-0440-2","volume":"8","author":"M Wirtz","year":"2018","unstructured":"Wirtz M, Schmidt A, Schottelius M, Robu S, G\u00fcnther T, Schwaiger M, et al. Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. EJNMMI Res. 2018;8:84.","journal-title":"EJNMMI Res"},{"key":"963_CR55","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.122.264296","volume":"64","author":"GJR Cook","year":"2023","unstructured":"Cook GJR, Wong WL, Sanghera B, Mangar S, Challapalli A, Bahl A, et al. Eligibility for \u00b9\u2077\u2077Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of \u2076\u2078Ga-PSMA-11 and \u2079\u2079Tc-MIP-1404 in metastatic castration-resistant prostate cancer. J Nucl Med. 2023;64:227\u201331.","journal-title":"J Nucl Med"},{"key":"963_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-021-00123-2","volume":"6","author":"N Gillings","year":"2021","unstructured":"Gillings N, Hjelstuen O, Ballinger J, Behe M, Decristoforo C, Elsinga P, et al. Guideline on current good radiopharmacy practice (cGRPP) for the small-scale Preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2021;6:1\u201322.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"963_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-019-0059-2","volume":"4","author":"SW Schwarz","year":"2019","unstructured":"Schwarz SW, Decristoforo C. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations. EJNMMI Radiopharm Chem. 2019;4:1\u20135.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"963_CR58","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1097\/MNM.0000000000002009","volume":"46","author":"MFA Fadzil","year":"2025","unstructured":"Fadzil MFA, Rohani MFM, Onny MAA, Ashhar Z, Said MA, Mahamood M, et al. Synthesis and clinical evaluation of cyclotron-produced [\u2076\u2078Ga]PSMA-11 and [\u00b9\u2078F]PSMA-1007 for prostate cancer imaging. Nucl Med Commun. 2025;46:872\u201383.","journal-title":"Nucl Med Commun"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-025-00963-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-025-00963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:03:11Z","timestamp":1770454991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-025-00963-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1007\/s13139-025-00963-9","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"29 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve any human participants, human data, or human biological material. It is a narrative review and therefore does not require ethics approval or informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"During the preparation of this work, the authors used ChatGPT (OpenAI) for language refinement, including grammar checking and proofreading. Following the use of this tool, the authors thoroughly reviewed and edited the content to ensure accuracy and appropriateness. The authors take full responsibility for the integrity and content of the final publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI in Scientific writing"}},{"value":"Muhammad Fakhrurazi Ahmad Fadzil and Akram Al-Ibraheem serves as the National Counterpart in the IAEA RAS6111 project which aim to enhance the management of cancer through capacity buildings in theranostics within the region.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s Information"}},{"value":"This manuscript has not been posted on any preprint server.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Preprint Sharing"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Number"}},{"value":"Akram Al-Ibraheem is an editorial board member of Nuclear Medicine and Molecular Imaging. Muhammad Fakhrurazi Ahmad Fadzil, Zarif Ashhar, Azahari Kasbollah, Zaitulhusna Md Safee and Siti Fazira Edzua Jamaludin declare that they have no conflict of interest.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}